This patient received intramuscular injections of either Aastrom’s tissue repair cells (TRCs) or electrolyte solution (placebo) for the treatment of critical limb ischemia (CLI), the end-stage of peripheral arterial disease. TRC-based cellular therapies are produced from a small sample of bone marrow taken from a patient. ASTM’s TRC technology greatly expands the cell populations for direct delivery to the damaged tissues of the same patient.
Aastrom’s (NASDAQ:ASTMD) ticker symbol will revert back (dropping the “D” designation) to ASTM as of 3/18/10. ASTM’s reverse stock split which became effective (2/18/10), has been trading on a post-split basis under the temporary trading symbol “ASTMD” for approximately 20 trading days.
Can Advanced Cell Technology (ACTC.OB) continue its existence and access to further capital requirements to move their programs to the clinic? I believe that Bill Caldwell, Bob Lanza and ACTC.OB who have lasted this long through many, many travails … with the right financing and agreements (with past investors and holders of debentures) … could … make it but, the jury is still out.
ReNeuron Group (RENE.L) announced the placing of 94.4 M new ordinary shares with existing and new institutional and qualifying individual shareholders on 2/22/10. This placement was comprised 2 closings and will trade on AIM.
Reported a lower FY09 net loss of $23.216 M or $0.65 per share with higher revenues versus a net loss of $30.036 M, or $1.12 per share for FY08.
Reported a smaller FY09 net loss of $27.02 M or $0.25 per share, an increase in revenues but, increased operational losses; versus a net loss of $29.08 M, or $0.35 per share for 2008.
We are all looking for any signal that will propel a stock and ONE indicator is the CEO investing his own money in ASTMD. CEO’s “direct” share ownership should be a factor of significance, but should not be confused with option or grant holdings. Timothy Mayleben, the new CEO filed a Form 4, this week with the SEC. Read more…
Opexa Therapeutics reported (3/5/10) a net loss of $1.43 M or $0.11 per diluted share for FY09 compared to $11.85 M or $1.12 per diluted share in FY08. FY09 highlights:
- The pivotal point in the year was the completion of the stem cell transaction with Novartis (NVS) Pharmaceuticals for an upfront payment of $3 M and potential technology transfer milestone payments totaling another $1 M (with total potential payments from the deal that could exceed $50 M),
ASTMD reported the final patient treatment in the ongoing cardiac regeneration US P 2 surgical clinical trial designated IMPACT-DCM. Treated at Emory University Hospital Midtown in Atlanta, GA, this patient received direct injections of ASTMD’s tissue repair cells for the treatment of dilated cardiomyopathy (DCM), a severe form of congestive heart failure in which the heart becomes weakened and enlarged and cannot pump blood efficiently.
- With the treatment of the final patient in this trial, Aastrom is positioned to report 6 month interim data on all enrolled patients in late 2010.